03.01.2024
The Barbara Davis Center (BDC) has been active in designing and conducting type 1 diabetes (T1D) studies aiming to prevent type 1 diabetes and extend insulin production (the honeymoon) in people with newly diagnosed type 1 diabetes for over 25 years. The BDC is the Colorado home for the Type 1 Diabetes TrialNet and the BDC Type 1 Diabetes Prevention Teams.
Type 1 Diabetes Prevention and Intervention
Youth and adults who screen positive for type 1 diabetes-related islet autoantibodies through TrialNet are offered free metabolic monitoring for progression to T1D and can participate in T1D clinical prevention trials. People who do not have a family history of T1D but have documented type 1 diabetes-related islet autoantibodies from another lab or study are able to confirm their antibody status by screening in the TrialNet Pathway to Prevention Study in order to have access to T1D prevention clinical trials.
The Prevention Team at the BDC has been at the forefront of performing clinical trials to delay progression to T1D and to arrest the disease process in newly diagnosed T1D patients. We are proud to have been a critical part of the TrialNet study that led to the first FDA approved therapy to delay T1D onset, Tzield. We have ongoing clinical trials testing therapies to delay and prevent the onset of T1D. We also offer a variety of studies with novel therapies to preserve the health of surviving insulin producing b-cells and to therefore prolong the honeymoon phase. We have new studies opening every few months. If you have been diagnosed in the past two years and are interested in learning more about our current clinical trials, please contact the BDC Prevention Team at 720-346-1034 or hali.broncucia@cuanschutz.edu or visit https://www.trialnet.org or https://clinicaltrials.gov.
Principal investigator: Andrea Steck, MD
Study coordinator: Hali Broncucia (303) 724-7526
